Eteng Pharmaceuticals completed the B-round financing funds will be used to develop cancer research and development pipeline.

ETSIN PHARMACEUTICALS (EOC) RECENTLY ANNOUNCED THAT IT HAS RECEIVED $32 MILLION IN ROUND B FINANCING TO DEVELOP A CANCER RESEARCH AND DEVELOPMENT PIPELINE, INCLUDING CLINICAL TRIALS AND REGISTRATION OF TWO INNOVATIVE DRUGS IN CHINA. According to reports, this round of financing by Taikang Investment through the Shandong State-controlled Taikang Industrial Development Fund, EOC's A-round financing lead investors - Sequoia China, together with Handing Asia Pacific also participated.
is understood that The EOC is committed to rapidly developing and commercializing innovative cancer drugs worldwide in China. The funds from this round of financing will be used to further develop the EOC's mid- and late-stage clinical product pipeline and introduce more late-stage oncology product projects in order to bring newer and better treatment options to Chinese patients.
" top investment fund has strengthened our strategic goals, and we want to bring to more cancer patients the world's leading, unique cancer treatment products. "In China, through our unique approach to collaboration and extensive commercialization experience, as well as our superior production and localization development capabilities, EOC has been able to gain a competitive advantage in china's ever-evolving clinical and regulatory environment and gain a foothold in the fast-growing Chinese medical market."
is understood that EOC has introduced a number of clinical phases of heavy-duty oncology products from the world's leading biopharmaceutical companies, and is committed to clinical trials and marketing of pharmaceuticals in China and around the world. The company has a rich product pipeline, including two small molecule innovation products will enter the third phase of clinical registration in 2018, respectively for breast and stomach cancer treatment. In addition, the company has a new biologic pipeline for tumor immunotherapy and tumor metastasis.
"EOC is building a strong platform for innovative pharmaceutical companies from around the world to enter China, " said Taikang Investment, "we are pleased to support Dr. Zou and his world-class team at this exciting stage of EOC's development." They are using their expertise and ability to benefit patients who currently have little or no treatment. "
.